Cargando…
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting
(1) Background: Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor with excellent activity against the multidrug-resistant (MDR) P. aeruginosa. Continuous infusion (CI) dosing allows the optimization of pharmacokinetic and pharmacodynamic (PK/PD) properties of β-lactam antibiotic...
Autores principales: | Venuti, Francesco, Gaviraghi, Alberto, De Nicolò, Amedeo, Stroffolini, Giacomo, Longo, Bianca Maria, Di Vincenzo, Alessia, Ranzani, Fabio Antonino, Quaranta, Matilde, Romano, Francesca, Catellani, Eleonora, Marchiaro, Carlotta, Cinnirella, Giacoma, D’Avolio, Antonio, Bonora, Stefano, Calcagno, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376517/ https://www.ncbi.nlm.nih.gov/pubmed/37508309 http://dx.doi.org/10.3390/antibiotics12071214 |
Ejemplares similares
-
Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020) -
Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022) -
Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022) -
1926. Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy
por: Jones, Bruce M, et al.
Publicado: (2018) -
1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)